| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/22/2008 | US20080119471 1-((4-chlorophenoxy)methyl)carbonyl-2-methyl-4-(4-fluorobenzyl)piperazine; chemokine receptor CCR1 antagonist; chemokine (MIP-1 alpha and RANTES) inhibitor; antiinflammatory agent; multiple sclerosis, rheumatoid arthritis |
| 05/22/2008 | US20080119468 Phthalazine, aza-and diaza-phthalazine compounds and methods of use |
| 05/22/2008 | US20080119467 Purine Derivatives, Compositions Containing Them and Use Thereof |
| 05/22/2008 | US20080119466 1-(4-Chloro-3-(trifluoro-methyl)phenyl)-3-(4-imidazo-[4,5-c]pyridin-1-ylphenyl)urea; Raf, a serine-threonine protein kinase inhibitor; Raf/MEK/ERK cascade in proliferation of human cancer cells; anticarcinogenic agent; psoriasis, atherosclerosis, chronic rheumatoid arthritis and diabetes |
| 05/22/2008 | US20080119463 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML) |
| 05/22/2008 | US20080119447 6-alkoxyalkyl estradiol derivatives and methods of use |
| 05/22/2008 | US20080119444 Methods and compositions for the treatment of cancer |
| 05/22/2008 | US20080119434 Sir2a-based therapeutic and prophylactic methods |
| 05/22/2008 | US20080119430 Compositions and Methods for Angiogenesis-Related Molecules and Treatments |
| 05/22/2008 | US20080119425 administering biodrug oligonucleotide anticarcinogenic agents for treating breast cancer, prostate cancer, bladder cancer, ovarian cancer, lung cancer, renal cancer, melanoma, and pancreatic cancer; gene expression inhibition |
| 05/22/2008 | US20080119421 producing a synchronized cells by administering a cell cycle arresting drug, then adding a microtubule stabilizing drug, and applying mechanical vibrational energy ultrasound; drug deliverying anticarcinogenic agent directed to be more toxic to cancer cells than normal cells |
| 05/22/2008 | US20080119407 Vitamin D Receptor Modulators |
| 05/22/2008 | US20080119403 Haparin-Binding Protein Modified with Heparan Sulfate Sugar Chains, Process for Producing the Same and Pharmaceutical Compositions Containing the Same |
| 05/22/2008 | US20080119402 Compositions and methods for the inhibition of dishevelled proteins |
| 05/22/2008 | US20080119398 Modified Thioredoxin |
| 05/22/2008 | US20080119397 Kahalalide Compositions |
| 05/22/2008 | US20080118576 Prediction of an agent's or agents' activity across different cells and tissue types |
| 05/22/2008 | US20080118567 Medicaments for Chemotherapeutic Treatment of Disease |
| 05/22/2008 | US20080118562 Encapsulated by a biocompatible polymer shell; decreased toxicity of anticarcinogenic agents; side effect reduction |
| 05/22/2008 | US20080118560 Spray congealed 5-amido-7-benzyl(oxy or amino)imidazo[1,2-a]pyridines, at least one each of hydrophilic and hydrophobic matrix formers; antisecretory agents with improved water solubility, bioavailability and pharmacokinetics |
| 05/22/2008 | US20080118522 Using lymphocyte receptor specific immunoglobulins to treat and prevent viral infection, asthma, cardiovascular, autoimmune, cell proliferative and inflammatory disorders |
| 05/22/2008 | US20080118513 Treatment of immune disorders with antibodies to costimulating polypeptide of T cells |
| 05/22/2008 | US20080118511 PD-L2 Molecules: Novel PD-1 Ligands and Uses Therefor |
| 05/22/2008 | US20080118510 Vegf-related protein |
| 05/22/2008 | US20080118505 Reagents and treatment methods for autoimmune diseases |
| 05/22/2008 | US20080118499 Using concentration of golgi-localized, gamma adaptin ear-containing, ARF-binding (GGA) as diagnostic indicator of beta-site amyloid precursor protein cleaving enzyme (BACE) activity and prognostic tool for detection of cardiovascular, nervous sytem and cell proliferative disorders |
| 05/22/2008 | US20080118481 Mononuclear phagocytes in therapeutic drug delivery |
| 05/22/2008 | US20080118433 Preparation and method utilizing radiolabeled chlorotoxin |
| 05/22/2008 | CA2702370A1 Compositions and methods for immunotherapy |
| 05/22/2008 | CA2669820A1 Derivatives of 18-amino substituted analogs of the geldamycin hydroquinon with cytotoxic activity for the treatment of cancer |
| 05/22/2008 | CA2669800A1 Nerve elongation promoter and elongation inhibitor |
| 05/22/2008 | CA2669704A1 Sulfoximines as kinase inhibitors |
| 05/22/2008 | CA2669596A1 Compounds and methods for inhibiting the interaction of bcl proteins with binding partners |
| 05/22/2008 | CA2669523A1 Aptamer against midkine and use thereof |
| 05/22/2008 | CA2669520A1 Methods of treating cancer using sirna molecules directed against cd24 |
| 05/22/2008 | CA2669357A1 Pyrroline derivatives against cell releasing tumor necrosis factor, preparation methods and uses thereof |
| 05/22/2008 | CA2669158A1 Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide |
| 05/22/2008 | CA2669131A1 Polymorphisms predictive of anthracycline-induced cardiotoxicity |
| 05/22/2008 | CA2668714A1 Methods of treating, diagnosing or detecting cancer |
| 05/22/2008 | CA2668673A1 Methods for improved engraftment following stem cell transplantation |
| 05/22/2008 | CA2668503A1 Cancerous disease modifying antibodies 180706-01 |
| 05/22/2008 | CA2668496A1 Cancerous disease modifying antibodies |
| 05/22/2008 | CA2668484A1 Cancerous disease modifying antibodies 180706-02 |
| 05/22/2008 | CA2668026A1 Aminobenzocycloheptene derivatives, methods for preparing the same and uses thereof in therapy |
| 05/22/2008 | CA2667128A1 Therapeutic use of at least one botulic neurotoxin in the treatment of pain induced by at least one antineoplastic agent |
| 05/22/2008 | CA2666903A1 Thrombin receptor antagonists based on the modified tricyclic unit of himbacine |
| 05/22/2008 | CA2665698A1 Use of spiro-oxindole compounds as therapeutic agents |
| 05/22/2008 | CA2654000A1 Anti-dll4 antibodies and methods using same |
| 05/22/2008 | CA2646611A1 Combinatorial therapy |
| 05/21/2008 | EP1923465A1 Inhibitor protein for the WNT signal pathway |
| 05/21/2008 | EP1923463A1 Cancer-rejection antigen peptide derived from glypican-3 (gpc3) for use in hal-a2-positive patient and pharmaceutical comprising the antigen |
| 05/21/2008 | EP1923391A1 Substituted heterocyclic compounds, method for preparing same and pharmaceutical compositions containing them. |
| 05/21/2008 | EP1923386A2 Carbamate caspase inhibitors and uses thereof |
| 05/21/2008 | EP1923072A1 Prophylactic/therapeutic agent for cancer |
| 05/21/2008 | EP1923053A1 Pharmaceutical compositions comprising nilotinib or its salt |
| 05/21/2008 | EP1922321A1 Pyrazoloý1,5-a¨pyrimidine compounds and pharmaceutical compositions containing them |
| 05/21/2008 | EP1922317A2 Amide and carbamate derivatives of n-{2-ý4-amino-2- (ethoxymethyl)-1h-imidazoý4,5-c¨quinolin-1-yl¨-1,1-dimethylethyl}methanesulfonamide and methods |
| 05/21/2008 | EP1922316A1 Benzimidazole thiophene compounds as plk modulators |
| 05/21/2008 | EP1922314A1 Delta and epsilon crystal forms of imatinib mesylate |
| 05/21/2008 | EP1922312A1 Thiazole compounds and their use as pgd2 antagonists |
| 05/21/2008 | EP1922310A2 Triazole derivatives useful as axl inhibitors |
| 05/21/2008 | EP1922309A1 N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof |
| 05/21/2008 | EP1922307A2 Heterocyclic inhibitors of mek and methods of use thereof |
| 05/21/2008 | EP1922094A1 Methods and devices for lymphatic targeting |
| 05/21/2008 | EP1922087A2 Method for the preparation of polymeric conjugates of doxorubicin with ph-controlled release of the drug |
| 05/21/2008 | EP1922086A1 Targeted protein kinase c inhibitors and uses thereof |
| 05/21/2008 | EP1922085A1 Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms |
| 05/21/2008 | EP1922080A2 Methods for treating b-cell malignancies using taci-ig fusion molecule |
| 05/21/2008 | EP1922079A2 Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules |
| 05/21/2008 | EP1922077A1 Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment |
| 05/21/2008 | EP1670487A4 Therapeutic formulations |
| 05/21/2008 | EP1603557A4 Synthesis of peloruside a and analogs thereof for use as antitumor agents |
| 05/21/2008 | EP1581238B1 Improvements in or relating to immune functions |
| 05/21/2008 | EP1482981B1 Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy |
| 05/21/2008 | EP1482924B1 Cathepsin cysteine protease inhibitors |
| 05/21/2008 | EP1448591B1 17alpha-alkyl-17beta-oxy-estratrienes and intermediates for the production thereof, and use of said 17alpha-alkyl-17beta-oxy-estratrienes for producing medicaments and pharmaceutical preparations |
| 05/21/2008 | EP1385508B1 Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 05/21/2008 | EP1372652B1 Combination of docetaxel and flavopiridol |
| 05/21/2008 | EP1366158B1 Trp8 markers for cancer |
| 05/21/2008 | EP1362027B1 Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical |
| 05/21/2008 | EP1319069B1 Compositions and methods for the therapy and diagnosis of lung cancer |
| 05/21/2008 | EP1287130B1 Mammalian cytokine receptor subunit proteins, related reagents and methods |
| 05/21/2008 | EP1284734B1 Isoquinoline derivatives as protein kinase inhibitors |
| 05/21/2008 | EP1265911B1 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents |
| 05/21/2008 | EP1227837B1 Method of inducing and/or enhancing an immune response to tumor antigens |
| 05/21/2008 | EP1183253B1 C7 ester substituted taxanes as antitumor agents |
| 05/21/2008 | EP1161262B1 SURFACE LOCALIZED COLLIGIN/HsP47 IN CARCINOMA CELLS |
| 05/21/2008 | EP1150714B1 Methods for inhibiting brain tumor growth |
| 05/21/2008 | EP1078002B1 Peptide antiangiogenic drugs |
| 05/21/2008 | EP1054687B1 Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas |
| 05/21/2008 | EP0924986B1 Antioxidant derived from lentil and its preparation and uses |
| 05/21/2008 | EP0831938B1 Radiolabeled peptide compositions for site-specific targeting |
| 05/21/2008 | EP0781138B1 Lipid analogs for treating viral infections |
| 05/21/2008 | DE102006054535A1 Progesteronrezeptorantagonisten Progesterone receptor antagonists |
| 05/21/2008 | CN101184840A Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |
| 05/21/2008 | CN101184752A Pyrimidine derivatives for use as anticancer agents |
| 05/21/2008 | CN101184751A Quinazolines and their use as AURORA kinase inhibitors |
| 05/21/2008 | CN101184750A Pyrimidines as IGF-inhibitors |
| 05/21/2008 | CN101184730A New hybrid oligomers. their preparation process and pharmaceutical compositions containing them |
| 05/21/2008 | CN101184506A Methods and compositions for modulating hyperstabilized c-met |